The efficacy of CP7_E2alf: an animal study involving piglets from C–strain vaccinated sows

Publication: Research - peer-reviewConference abstract for conference – Annual report year: 2012

Standard

The efficacy of CP7_E2alf: an animal study involving piglets from C–strain vaccinated sows. / Rangelova, Desislava Yordanova; Nielsen, Jens; Strandbygaard, Bertel; Blome, Sandra; Uttenthal, Åse.

2012. Abstract from Annual Meeting of the National Reference Laboratories of CSF, Hannover, Germany.

Publication: Research - peer-reviewConference abstract for conference – Annual report year: 2012

Harvard

Rangelova, DY, Nielsen, J, Strandbygaard, B, Blome, S & Uttenthal, Å 2012, 'The efficacy of CP7_E2alf: an animal study involving piglets from C–strain vaccinated sows' Annual Meeting of the National Reference Laboratories of CSF, Hannover, Germany, 01/07/12 - 01/07/12,

APA

Rangelova, D. Y., Nielsen, J., Strandbygaard, B., Blome, S., & Uttenthal, Å. (2012). The efficacy of CP7_E2alf: an animal study involving piglets from C–strain vaccinated sows. Abstract from Annual Meeting of the National Reference Laboratories of CSF, Hannover, Germany.

CBE

Rangelova DY, Nielsen J, Strandbygaard B, Blome S, Uttenthal Å. 2012. The efficacy of CP7_E2alf: an animal study involving piglets from C–strain vaccinated sows. Abstract from Annual Meeting of the National Reference Laboratories of CSF, Hannover, Germany.

MLA

Vancouver

Rangelova DY, Nielsen J, Strandbygaard B, Blome S, Uttenthal Å. The efficacy of CP7_E2alf: an animal study involving piglets from C–strain vaccinated sows. 2012. Abstract from Annual Meeting of the National Reference Laboratories of CSF, Hannover, Germany.

Author

Rangelova, Desislava Yordanova; Nielsen, Jens; Strandbygaard, Bertel; Blome, Sandra; Uttenthal, Åse / The efficacy of CP7_E2alf: an animal study involving piglets from C–strain vaccinated sows.

2012. Abstract from Annual Meeting of the National Reference Laboratories of CSF, Hannover, Germany.

Publication: Research - peer-reviewConference abstract for conference – Annual report year: 2012

Bibtex

@misc{76fb38e036c74620ab1a25e36cb580fb,
title = "The efficacy of CP7_E2alf: an animal study involving piglets from C–strain vaccinated sows",
author = "Rangelova, {Desislava Yordanova} and Jens Nielsen and Bertel Strandbygaard and Sandra Blome and Åse Uttenthal",
note = "Oral presentation at the 2012 Annual Meeting of the National Reference Laboratories of CSF",
year = "2012",
type = "ConferencePaper <importModel: ConferenceImportModel>",

}

RIS

TY - ABST

T1 - The efficacy of CP7_E2alf: an animal study involving piglets from C–strain vaccinated sows

A1 - Rangelova,Desislava Yordanova

A1 - Nielsen,Jens

A1 - Strandbygaard,Bertel

A1 - Blome,Sandra

A1 - Uttenthal,Åse

AU - Rangelova,Desislava Yordanova

AU - Nielsen,Jens

AU - Strandbygaard,Bertel

AU - Blome,Sandra

AU - Uttenthal,Åse

PY - 2012

Y1 - 2012

N2 - Outbreaks of Classical Swine Fever (CSF) in the European Union have caused enormous economical losses. To facilitate the possibility of free trade with pigs and their products, a chimeric live DIVA vaccine CP7_E2alf was developed. Most likely, passive immunity against CSF virus in populations previously vaccinated with C-strain interferes with the efficacy of CP7_E2alf vaccination. To study the interaction with maternal antibodies, the efficacy of CP7_E2alf in piglets from C-strain vaccinated sows was examined. At 5 or at 8 weeks of age, piglets were vaccinated with CP7_E2alf. The vaccinated piglets together with mock-vaccinated littermate controls were challenged 2 weeks post vaccination with highly virulent CSFV Kozlov. The results showed that CP7_E2alf is effective in preventing mortality, severe clinical signs and pathological lesions in piglets vaccinated at 5 or at 8 weeks of age. Interestingly, the antibodies in the mock-vaccinated control piglets partly neutralized the challenge virus. In earlier studies CSFV Koslov has resulted in 100% mortality in naïve piglets, in this study mortality was reduced to 30% in the piglets infected at 7 weeks of age and to 50% in the piglets infected at 10 weeks of age. In the present study optimal time point for vaccination of piglets with passive immunity was found to be 5 weeks of age.

AB - Outbreaks of Classical Swine Fever (CSF) in the European Union have caused enormous economical losses. To facilitate the possibility of free trade with pigs and their products, a chimeric live DIVA vaccine CP7_E2alf was developed. Most likely, passive immunity against CSF virus in populations previously vaccinated with C-strain interferes with the efficacy of CP7_E2alf vaccination. To study the interaction with maternal antibodies, the efficacy of CP7_E2alf in piglets from C-strain vaccinated sows was examined. At 5 or at 8 weeks of age, piglets were vaccinated with CP7_E2alf. The vaccinated piglets together with mock-vaccinated littermate controls were challenged 2 weeks post vaccination with highly virulent CSFV Kozlov. The results showed that CP7_E2alf is effective in preventing mortality, severe clinical signs and pathological lesions in piglets vaccinated at 5 or at 8 weeks of age. Interestingly, the antibodies in the mock-vaccinated control piglets partly neutralized the challenge virus. In earlier studies CSFV Koslov has resulted in 100% mortality in naïve piglets, in this study mortality was reduced to 30% in the piglets infected at 7 weeks of age and to 50% in the piglets infected at 10 weeks of age. In the present study optimal time point for vaccination of piglets with passive immunity was found to be 5 weeks of age.

ER -